[1]中国抗癌协会妇科肿瘤专业委员会.子宫内膜癌诊断与治疗指南（2021年版）[J].中国癌症杂志,2021,31(06):501-512.DOI:10.19401/j.cnki.1007-3639.2021.06.08.[2]Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza MR, Sessa C; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2016 Jan;27(1):16-41.[3]Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, Heintz AP, Ngan HY, Pecorelli S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43.[4]Fleming GF. Second-Line Therapy for Endometrial Cancer: The Need for Better Options. J Clin Oncol. 2015 Nov 1;33(31):3535-40. doi: 10.1200/JCO.2015.61.7225. Epub 2015 Jul 20. Erratum in: J Clin Oncol. 2015 Dec 20;33(36):4316. PMID: 26195695.[5]Clemen CS, Herr C, Hövelmeyer N, Noegel AA. The lack of annexin A7 affects functions of primary astrocytes. Exp Cell Res. 2003 Dec 10;291(2):406-14. doi: 10.1016/j.yexcr.2003.07.012. PMID: 14644162.[6]Leighton X, Eidelman O, Jozwik C, Pollard HB, Srivastava M. ANXA7-GTPase as Tumor Suppressor: Mechanisms and Therapeutic Opportunities. Methods Mol Biol. 2017;1513:23-35. doi: 10.1007/978-1-4939-6539-7_3. PMID: 27807828.[7]Hsu PI, Huang MS, Chen HC, Hsu PN, Lai TC, Wang JL, Lo GH, Lai KH, Tseng CJ, Hsiao M. The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer. J Surg Oncol. 2008 Jun 1;97(7):609-14. doi: 10.1002/jso.21046. PMID: 18449914.[8]Mo HQ, Tian FJ, Li X, Zhang J, Ma XL, Zeng WH, Lin Y, Zhang Y. ANXA7 regulates trophoblast proliferation and apoptosis in preeclampsia. Am J Reprod Immunol. 2019 Dec;82(6):e13183. doi: 10.1111/aji.13183. Epub 2019 Sep 28. PMID: 31446642.[9]WARBURG O. On the origin of cancer cells. Science. 1956;123(3191):309-314. doi:10.1126/science.123.3191.309[10]曹丽娟,舒新军,高春燕.C-erbB-2、miR-103a-3p、ANXA7在子宫内膜癌组织中的表达及相关性研究[J].中国性科学,2021,30(12):79-83.[11]Yang W, Lu Z. Pyruvate kinase M2 at a glance. J Cell Sci. 2015 May 1;128(9):1655-60. doi: 10.1242/jcs.166629. Epub 2015 Mar 13. PMID: 25770102; PMCID: PMC4446733.[12]Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009 May 22;324(5930):1029-33. doi: 10.1126/science.1160809. PMID: 19460998; PMCID: PMC2849637.[13]Yang W, Lu Z. Pyruvate kinase M2 at a glance. J Cell Sci. 2015 May 1;128(9):1655-60. doi: 10.1242/jcs.166629. Epub 2015 Mar 13. PMID: 25770102; PMCID: PMC4446733.[14]Jiang Y, Wang Y, Wang T, Hawke DH, Zheng Y, Li X, Zhou Q, Majumder S, Bi E, Liu DX, Huang S, Lu Z. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells. Nat Commun. 2014 Nov 21;5:5566. doi: 10.1038/ncomms6566. PMID: 25412762; PMCID: PMC4259466.[15]Luo W, Semenza GL. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012 Nov;23(11):560-6. doi: 10.1016/j.tem.2012.06.010. Epub 2012 Jul 21. PMID: 22824010; PMCID: PMC3466350.[16]谷守娟.PKM2在子宫内膜癌发病中的作用及其机制研究[D].天津医科大学,2016.[17]Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13;309(15):883-7. doi: 10.1056/NEJM198310133091503. PMID: 6310399.[18]Li J, Wang X, Qu W, Wang J, Jiang SW. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. Clin Chim Acta. 2019 Jan;488:215-220. doi: 10.1016/j.cca.2018.11.011. Epub 2018 Nov 7. PMID: 30414437.[19]Piovano E, Attamante L, Macchi C, Cavallero C, Romagnolo C, Maggino T, Landoni F, Gadducci A, Sartori E, Gion M, Zola P. The role of HE4 in ovarian cancer follow-up: a review. Int J Gynecol Cancer. 2014 Oct;24(8):1359-65. doi: 10.1097/IGC.0000000000000218. PMID: 25054447.[20]Innao P, Pothisuwan M, Pengsa P. Does Human Epididymis Protein 4 (HE4) Have a Role in Prediction of Recurrent Epithelial Ovarian Cancer. Asian Pac J Cancer Prev. 2016;17(9):4483-4486. PMID: 27797265.[21]Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC Jr, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009 Jan;112(1):40-6. doi: 10.1016/j.ygyno.2008.08.031. Epub 2008 Oct 12. PMID: 18851871; PMCID: PMC3594094.[22]Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008 Aug;110(2):196-201. doi: 10.1016/j.ygyno. 2008.04.002. Epub 2008 May 21. PMID: 18495222; PMCID: PMC3594093.[23]Li J, Wang X, Qu W, Wang J, Jiang SW. Comparison of serum human epididymis protein 4 and CA125 on endometrial cancer detection: A meta-analysis. Clin Chim Acta. 2019 Jan;488:215-220. doi: 10.1016/j.cca.2018.11.011. Epub 2018 Nov 7. PMID: 30414437.
